companydata.dkcompanydata.dk

ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S: Financial statements 2015

CVR: 32323502

Source: annual report 2015, Danish Business Authority

01/01/2015 – 31/12/2015

ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S (CVR 32323502) has filed annual accounts for 2015. In 2015, the company reported a gross profit of EUR 5,370,361 and a net result of EUR 5,606,878 compared with EUR 5,786,449 the year before. That is a decrease of 1.6% compared with the year before. Equity in the 2015 report amounted to EUR 10,857,730. The solvency ratio was 77.9%.

Gross Profit
EUR 5,370,361
Profit/Loss
EUR 5,606,878
Equity
EUR 10,857,730
Total Assets
EUR 13,935,811

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2015-5.4M EUR5.6M EUR10.9M EUR-
2014-5.5M EUR5.8M EUR5.3M EUR-
2013-18.5M16.3M19.1M-

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

Events in 2015

ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S: The 2014 annual report is outMay 13, 2015

ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S has published its annual report for 2014. Gross profit came to DKK 5,456,890, and the net result was DKK 5,786,449.

About ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S

ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ACP 30.06.2012 1 A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR 5,567,000 and a net result of EUR -5,238,000 compared with EUR 5,001,000 the year before. Equity in the 2025 report amounted to EUR -38,639,000.

Source: annual report 2025, Danish Business Authority